Research & Development
Further advances in the clinic for obesity and oncology will provide a pipeline of news in 2025, as the pharmaceutical industry sharpens its focus on scientific advances with GLP-1s and radiopharmaceuticals.
Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
Dreams of a future with early curative treatments drives wave of drug development in pre-surgical and perioperative treatment in many tumor types.
Radioligand therapies offer a resistance-proof mechanism that complements immuno-therapies and other drug classes. No wonder oncology players continue to pile in.
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.